NCT02436512 - Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide | Biotech Hunter

Timeline

Start Date

June 30, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

Inhaled Nitric Oxide

"The investigational product is inhaled nitric oxide delivered via nasal cannula or venturi mask with the GeNOsylTM Delivery System or GeNOsylTM Acute DS, during RHC as follows:~* (Dose 1): 5 ppm inhaled nitric oxide for 15 minutes~* (Dose 2): 40 ppm inhaled nitric oxide for 15 minutes"

Trial Locations (2)

15212

Allegheny General Hospital, Pittsburgh

35294

University of Alabama, Birmingham